Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-18 21:19 | 2026-06-16 | ONC | BeOne Medicines Ltd. | OYLER JOHN | Director, Officer | SELL | $265.55 | 3,693 | $980,686 | 0 |
| 2026-06-18 21:19 | 2026-06-16 | ONC | BeOne Medicines Ltd. | Wu Xiaobin | Officer | SELL | $266.76 | 1,357 | $361,997 | 0 |
| 2026-06-18 20:43 | 2026-06-16 | IRON | Disc Medicine, Inc. | Yu Jonathan Yen-Wen | Officer | OPT+S | $69.19 | 18,612 | $1,287,802 | 54,324 |
| 2026-06-18 20:30 | 2026-06-17 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $552.40 | 9,500 | $5,247,802 | 40,513 |
| 2026-06-18 20:30 | 2026-06-17 | CORT | CORCEPT THERAPEUTICS INC | MAHONEY DAVID L | Director | SELL | $84.53 | 20,000 | $1,690,506 | 26,147 |
| 2026-06-18 20:30 | 2026-06-16 | CORT | CORCEPT THERAPEUTICS INC | WILSON JAMES N | Director | SELL | $83.20 | 10,000 | $832,049 | 1,094,543 |
| 2026-06-18 20:31 | 2026-06-18 | UTHR | UNITED THERAPEUTICS Corp | MAHON PAUL A | Officer | OPT+S | $541.55 | 8,300 | $4,494,841 | 45,172 |
| 2026-06-18 20:18 | 2026-06-16 | STOK | Stoke Therapeutics, Inc. | Allan Jonathan | Officer | SELL | $29.95 | 1,457 | $43,637 | 18,086 |
| 2026-06-18 20:05 | 2026-06-17 | ASMB | ASSEMBLY BIOSCIENCES, INC. | Bjorkquist Jeanette M | Officer | SELL | $23.25 | 29 | $674 | 14,560 |
| 2026-06-18 16:18 | 2026-06-17 | ADTX | Aditxt, Inc. | DRW Securities, LLC | 10% owner | SELL | $0.01 | 126,772 | $1,001 | 0 |
| 2026-06-18 15:38 | 2026-06-16 | PRTA | PROTHENA CORP PUBLIC LTD CO | SCULLY WILLIAM P | 10% owner | BUY | $7.90 | 20,000 | $157,990 | 756,000 |
| 2026-06-18 12:37 | 2026-06-16 | LGND | LIGAND PHARMACEUTICALS INC | Sabba Stephen L | Director | OPT+S | $254.00 | 2,145 | $544,830 | 33,629 |
| 2026-06-17 20:05 | 2026-06-16 | UPB | Upstream Bio, Inc. | Houghton Adam | Officer | SELL | $6.10 | 700 | $4,270 | 23,601 |
| 2026-06-17 20:05 | 2026-06-16 | UPB | Upstream Bio, Inc. | Deykin Aaron | Officer | SELL | $6.10 | 895 | $5,460 | 33,197 |
| 2026-06-17 20:05 | 2026-06-16 | UPB | Upstream Bio, Inc. | Ambrose Allison | Officer | SELL | $6.10 | 477 | $2,910 | 16,048 |
| 2026-06-17 20:30 | 2026-06-16 | NRSN | NeuroSense Therapeutics Ltd. | Ben-Noon Alon | Officer | BUY | $0.80 | 250,000 | $200,000 | 4,534,233 |
| 2026-06-17 20:05 | 2026-06-16 | UPB | Upstream Bio, Inc. | Sutherland Everett Rand | Director, Officer | SELL | $6.10 | 2,095 | $12,780 | 70,812 |
| 2026-06-17 20:07 | 2026-06-16 | DYN | Dyne Therapeutics, Inc. | Friedl-Naderer Johanna | Officer | SELL | $18.33 | 145 | $2,658 | 154,208 |
| 2026-06-17 20:08 | 2026-06-16 | DYN | Dyne Therapeutics, Inc. | Kerr Douglas | Officer | SELL | $18.33 | 887 | $16,259 | 169,155 |
| 2026-06-17 20:12 | 2026-06-15 | VRTX | VERTEX PHARMACEUTICALS INC / MA | Bozic Carmen | Officer | SELL | $450.00 | 4,062 | $1,827,900 | 16,953 |
| 2026-06-17 20:30 | 2026-06-16 | NRSN | NeuroSense Therapeutics Ltd. | Eisenberg Or | Officer | BUY | $0.80 | 250,000 | $200,000 | 1,504,050 |
| 2026-06-17 20:14 | 2026-06-16 | KRRO | Korro Bio, Inc. | Chappell Todd | Officer | SELL | $10.83 | 3,168 | $34,309 | 16,964 |
| 2026-06-17 20:11 | 2026-06-16 | KRRO | Korro Bio, Inc. | Vincent Loic A | Officer | SELL | $10.83 | 3,418 | $37,017 | 18,297 |
| 2026-06-17 20:08 | 2026-06-16 | KRRO | Korro Bio, Inc. | Cerio Jeffrey | Officer | SELL | $10.83 | 6,609 | $71,575 | 35,293 |
| 2026-06-17 20:05 | 2026-06-16 | KRRO | Korro Bio, Inc. | Dolan Oliver | Officer | SELL | $10.83 | 3,383 | $36,638 | 18,099 |
| 2026-06-17 20:05 | 2026-06-15 | LFVN | Lifevantage Corp | Lewis Darwin | Director | BUY | $8.60 | 705 | $6,059 | 137,268 |
| 2026-06-17 20:07 | 2026-06-16 | DYN | Dyne Therapeutics, Inc. | Cox John | Director, Officer | SELL | $18.33 | 2,683 | $49,179 | 368,151 |
| 2026-06-17 20:23 | 2026-06-15 | ADTX | Aditxt, Inc. | HRT FINANCIAL LP | 10% owner | BUY | $0.01 | 2,114,344 | $29,601 | 344,964 |
| 2026-06-17 20:05 | 2026-06-16 | UPB | Upstream Bio, Inc. | GRAY MICHAEL | Officer | SELL | $6.10 | 853 | $5,203 | 28,795 |
| 2026-06-17 20:30 | 2026-06-15 | CORT | CORCEPT THERAPEUTICS INC | Mokari Atabak | Officer | OPT+S | $81.15 | 40,000 | $3,245,900 | 16,130 |
| 2026-06-18 01:18 | 2026-06-17 | MLYS | Mineralys Therapeutics, Inc. | Karydas Daphne | Director | OPT+S | $25.00 | 3,000 | $75,000 | 6,200 |
| 2026-06-18 01:18 | 2026-06-15 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Officer | OPT+S | $24.19 | 14,474 | $350,087 | 57,095 |
| 2026-06-18 00:40 | 2026-06-15 | ARQT | Arcutis Biotherapeutics, Inc. | Welgus Howard G. | Director | OPT+S | $24.58 | 4,731 | $116,281 | 37,743 |
| 2026-06-18 00:47 | 2026-06-15 | ARQT | Arcutis Biotherapeutics, Inc. | LIN SUE-JEAN | Director | SELL | $24.38 | 4,946 | $120,587 | 27,567 |
| 2026-06-18 00:25 | 2026-06-15 | SDEV | Stablecoin Development Corp | R01 Fund LP | 10% owner | SELL | $1.09 | 24,720 | $26,945 | 22,668,516 |
| 2026-06-18 00:25 | 2026-06-15 | SDEV | Stablecoin Development Corp | Framework Ventures IV L.P. | 10% owner | SELL | $1.09 | 24,720 | $26,945 | 22,668,516 |
| 2026-06-18 00:26 | 2026-06-15 | SDEV | Stablecoin Development Corp | Kazley Michael John | Director, Officer, 10% owner | SELL | $1.09 | 24,720 | $26,945 | 22,668,516 |
| 2026-06-17 23:56 | 2026-06-15 | TBPH | Theravance Biopharma, Inc. | Farnum Rhonda | Officer | SELL | $16.39 | 13,314 | $218,167 | 232,457 |
| 2026-06-17 23:45 | 2026-06-15 | ELVN | Enliven Therapeutics, Inc. | ORBIMED ADVISORS LLC | 10% owner | SELL | $45.02 | 281,408 | $12,668,988 | 7,388,902 |
| 2026-06-17 23:34 | 2026-06-15 | OTLC | Oncotelic Therapeutics, Inc. | Trieu Vuong | Director, Officer, 10% owner | BUY | $0.04 | 335,759 | $15,008 | 93,389,560 |
| 2026-06-17 23:12 | 2026-06-15 | NKTR | NEKTAR THERAPEUTICS | Zalevsky Jonathan | Officer | SELL | $60.71 | 5,538 | $336,212 | 15,437 |
| 2026-06-17 22:38 | 2026-06-15 | CTMX | CytomX Therapeutics, Inc. | Ogden Christopher | Officer | SELL | $3.05 | 1,624 | $4,953 | 295,324 |
| 2026-06-17 22:15 | 2026-06-15 | MLTX | MoonLake Immunotherapeutics | Reich Kristian | Officer | SELL | $19.01 | 150,000 | $2,851,005 | 2,824,551 |
| 2026-06-17 21:51 | 2026-06-15 | PHVS | Pharvaris N.V. | Modig Berndt | Director, Officer | SELL | $31.07 | 2,291 | $71,173 | 135,209 |
| 2026-06-17 21:26 | 2026-06-15 | IMNM | Immunome Inc. | Rosett Max | Officer | OPT+S | $18.23 | 60,000 | $1,093,800 | 54,037 |
| 2026-06-17 21:05 | 2026-06-16 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $549.80 | 9,500 | $5,223,069 | 40,513 |
| 2026-06-17 21:08 | 2026-06-17 | ETON | Eton Pharmaceuticals, Inc. | Adams Jennifer McKie | Director | OPT+S | $32.48 | 50,000 | $1,623,795 | 0 |
| 2026-06-17 20:55 | 2026-06-15 | KROS | Keros Therapeutics, Inc. | BIENAIME JEAN JACQUES | Director | BUY | $10.19 | 1,000 | $10,190 | 17,592 |
| 2026-06-17 20:56 | 2026-06-15 | QURE | uniQure N.V. | Potts Jeannette | Officer | SELL | $27.67 | 5,237 | $144,908 | 133,246 |
| 2026-06-17 21:02 | 2026-06-15 | QURE | uniQure N.V. | Balachandran Madhavan | Director | OPT+S | $27.85 | 10,000 | $278,500 | 43,254 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.